Tenax Therapeutics Says Late-Stage Trial Misses Primary, Secondary Endpoints
By Connor Hart
Tenax Therapeutics said a late-stage clinical trial of its treatment for pulmonary hypertension failed to meet its primary or key secondary endpoints.
The company on Monday said the treatment, TNX-103, didn't result in a statistically significant improvement in six-minute walk distances versus placebo, or improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.
Shares of Tenax tumbled 85%, to $2.07, in premarket trading.
Still, Tenax said it has identified a substantial beneficial treatment effect in patients with greater disease burden, and that the treatment was generally safe and well tolerated.
The company said it intends to request a Type C Meeting with the Food and Drug Administration to discuss revisions to the ongoing registrational development of TNX-103 for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction.
"Having reviewed the available trial results, I am encouraged we have a clear path forward," Stuart Rich.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 10, 2026 07:52 ET (11:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States